Advertisement

ImmuNext Inc., a Lebanon, N.H. company working on protein-based therapeutics to treat autoimmunity, cancer, transplantation rejection and infectious diseases, has licensed its technology in a deal potentially worth more than $150 million.

Advertisement
Advertisement